Literature DB >> 29462277

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Georgina Arrambide1, Mar Tintore1, Carmen Espejo1, Cristina Auger2, Mireia Castillo1, Jordi Río1, Joaquín Castilló1, Angela Vidal-Jordana1, Ingrid Galán1, Carlos Nos1, Raquel Mitjana2, Patricia Mulero1, Andrea de Barros2, Breogán Rodríguez-Acevedo1, Luciana Midaglia1, Jaume Sastre-Garriga1, Alex Rovira2, Manuel Comabella1, Xavier Montalban1,3.   

Abstract

The presence of oligoclonal bands in clinically isolated syndromes is an independent risk factor for developing multiple sclerosis and has been largely excluded from the more recent multiple sclerosis diagnostic criteria. Therefore, our objective was to explore the value of oligoclonal bands in the context of the 2010 McDonald criteria, especially in patients fulfilling exclusively dissemination in space at baseline. For this purpose, we selected 566 patients from a clinically isolated syndrome inception cohort who had IgG oligoclonal bands determination and sufficient data on baseline brain MRI to assess dissemination in space and time. We excluded the cases already fulfilling both dissemination in space and time and divided the remaining 398 into 'no dissemination in space and time' (n = 218), 'dissemination in space' (n = 164) and 'dissemination in time' (n = 16). We assessed Cox proportional hazards regression models with 2010 McDonald as the outcome, using 'no dissemination in space and time' with 0 lesions and negative oligoclonal bands as the reference for different subgroups according to oligoclonal bands status (positive/negative). To assess the diagnostic properties, we selected cases with a follow-up ≥3 years or fulfilling 2010 McDonald within 3 years of the clinically isolated syndrome (n = 314), and compared the performance of all 'dissemination in space' cases (n = 137) versus patients with 'dissemination in space' and positive oligoclonal bands (n = 101). The remaining patients classified as fulfilling 'dissemination in time' or 'no dissemination in space and time' were taken into account to calculate the diagnostic properties. The respective adjusted hazard ratios (95% confidence interval) were 1.5 (0.4-5.7) for 'no dissemination in space and time' with 0 lesions and positive oligoclonal bands, 3.1 (1.4-7.2) for 'no dissemination in space and time' with ≥1 lesions and negative oligoclonal bands, 7.4 (3.5-15.7) for 'no dissemination in space and time' with ≥1 lesions and positive oligoclonal bands, 10.4 (4.8-22.6) for 'dissemination in space' with negative oligoclonal bands, 15.3 (7.5-31.3) for 'dissemination in space' with positive oligoclonal bands, and 9.1 (3.5-23.4) for 'dissemination in time' (not subdivided due to the sample size). The specificity for all cases with 'dissemination in space' was 80.6 and increased to 88.1 after selecting those with positive oligoclonal bands. According to these results, we propose radiological dissemination in space at any time plus positive oligoclonal bands as an additional criterion for diagnosing multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29462277     DOI: 10.1093/brain/awy006

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  29 in total

1.  [Milestone or missed opportunity? : Commentary on the revision of the McDonald criteria 2017].

Authors:  Katrin Pape; Frauke Zipp
Journal:  Nervenarzt       Date:  2019-02       Impact factor: 1.214

Review 2.  Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.

Authors:  Andrew J Solomon; Robert T Naismith; Anne H Cross
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

Review 3.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

4.  High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis.

Authors:  Simon Gamraoui; Guillaume Mathey; Marc Debouverie; Catherine Malaplate; René Anxionnat; Francis Guillemin; Jonathan Epstein
Journal:  J Neurol       Date:  2019-02-01       Impact factor: 4.849

5.  Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis.

Authors:  M A Clarke; D Pareto; L Pessini-Ferreira; G Arrambide; M Alberich; F Crescenzo; S Cappelle; M Tintoré; J Sastre-Garriga; C Auger; X Montalban; N Evangelou; À Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-21       Impact factor: 3.825

6.  Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity.

Authors:  Harald Hegen; Klaus Berek; Florian Deisenhammer
Journal:  Wien Med Wochenschr       Date:  2022-02-08

Review 7.  Update on Multiple Sclerosis Molecular Biomarkers to Monitor Treatment Effects.

Authors:  Viviana Nociti; Marina Romozzi; Massimiliano Mirabella
Journal:  J Pers Med       Date:  2022-03-31

Review 8.  Coexistence of systemic lupus erythematosus and multiple sclerosis. A case report and literature review.

Authors:  Elisa Carolina Jácome Sánchez; María Ariana García Castillo; Victor Paredes González; Fernando Guillén López; Edgar Patricio Correa Díaz
Journal:  Mult Scler J Exp Transl Clin       Date:  2018-04-08

9.  Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Authors:  C E Leurs; Ham Twaalfhoven; B I Lissenberg-Witte; V van Pesch; I Dujmovic; J Drulovic; M Castellazzi; T Bellini; M Pugliatti; J Kuhle; L M Villar; J C Alvarez-Cermeño; R Alvarez-Lafuente; H Hegen; F Deisenhammer; L M Walchhofer; E Thouvenot; M Comabella; X Montalban; L Vécsei; C Rajda; D Galimberti; E Scarpini; A Altintas; K Rejdak; J L Frederiksen; G Pihl-Jensen; Peh Jensen; M Khalil; M M Voortman; F Fazekas; A Saiz; D La Puma; M Vercammen; L Vanopdenbosch; Bmj Uitdehaag; J Killestein; C Bridel; C Teunissen
Journal:  Mult Scler       Date:  2019-05-08       Impact factor: 6.312

10.  Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study.

Authors:  Klaus Berek; Gabriel Bsteh; Michael Auer; Franziska Di Pauli; Anne Zinganell; Thomas Berger; Florian Deisenhammer; Harald Hegen
Journal:  Front Immunol       Date:  2021-06-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.